ArticleWorld journal of gastroenterology2025
Recent advances in the diagnosis of celiac disease.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Celiac disease (CD) is a prevalent immune-mediated disorder triggered by gluten ingestion in genetically susceptible individuals. Primarily affecting the small intestine, CD can also have adverse systemic health effects. However, the majority of affected individuals remain undiagnosed because of asymptomatic or subclinical manifestations. While the diagnostic gold standard remains the combination of positive serum immunoglobulin A antibodies against tissue transglutaminase and villous atrophy on small intestinal biopsy, an evolving understanding of CD pathogenesis has elevated various serum biomarkers to increasingly important complementary diagnostic tools. This editorial aims to outline the scientific merits and potential limitations of serum biomarker assays for CD diagnosis, alongside their established and emerging clinical applications in both initial diagnosis and long-term disease monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.